

For immediate release Seinäjoki, Finland 7.2.2024

Eevia Health Plc has secured a credit line of SEK 7.2 million for working capital purposes to finance continued growth.

Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Råsunda Förvaltning AB, Upgrade Invest Nordic AB, and Renewable Ventures Nordic AB will provide a credit line for Eevia of up to SEK 7.2 million (EUR 640,000) giving the Company increased working capital flexibility to finance its continued growth. The term of the Credit line is until June 30, 2024, and it is unsecured. Interest is charged at two (2.0) percent per month and a five (5) percent arrangement fee.

Stein Ulve, Chief Executive Officer states: "Eevia had a transformative 2023 where we broadened our customer base and laid the foundation for strong growth in the years to come. The credit line provides for short-term working capital to continue with our strategic focus on expanding the business."

This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on February 7, 2024.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc Email: stein.ulve@eeviahealth.com Telephone: +358 400 22 5967



INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, Chaga mushroom, and pine bark, are wild harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) <u>EEVIA</u>.

To learn more, please visit <u>www.eeviahealth.com</u> or follow Eevia Health on LinkedIn@EeviaHealth.